(Q39381881)

English

Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

apoptotic process

0 references

1 reference

based on heuristic

inferred from title

2

object named as

Veronica Jove

0 references

Robert C Seeger

11

object named as

Robert Seeger

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Fan Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Veronica Jove

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ralf Buettner

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hong Xin

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Jun Wu

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yan Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sangkil Nam

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yibing Xu

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Tasnim Ara

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yves A DeClerck

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hua Yu

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Richard Jove

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cancer Biology and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

534-541

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

The STATs of cancer--new molecular targets come of age

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Stat3 as an oncogene

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Roles and regulation of stat family transcription factors in human breast cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19603

21 January 2018

Identifiers

10.4161/CBT.19603

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39381881&oldid=2185858409"